First Trust Advisors
IBRX icon

First Trust Advisors’s ImmunityBio IBRX Stock Holding History

First Trust Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-271,832
Closed -$669K – 2670
2025
Q3 		$669K Sell
271,832
-276,674
-50% -$713K ﹤0.01% 2240
2025
Q2 		$1.45M Buy
+548,506
New +$1.47M ﹤0.01% 1950
2025
Q1 		– Sell
-167,200
Closed -$428K – 2575
2024
Q4 		$428K Sell
167,200
-589,609
-78% -$2.46M ﹤0.01% 2295
2024
Q3 		$2.82M Sell
756,809
-130,811
-15% -$605K ﹤0.01% 1616
2024
Q2 		$5.61M Buy
+887,620
New +$5.85M 0.01% 1216
2023
Q2 		– Sell
-155,497
Closed -$283K – 2392
2023
Q1 		$283K Buy
155,497
+97,090
+166% +$302K ﹤0.01% 2248
2022
Q4 		$296K Sell
58,407
-16,962
-23% -$93.1K ﹤0.01% 2315
2022
Q3 		$375K Buy
75,369
+14,897
+25% +$67.9K ﹤0.01% 2295
2022
Q2 		$225K Buy
+60,472
New +$243K ﹤0.01% 2364
2021
Q3 		– Sell
-250,096
Closed -$3.57M – 2568
2021
Q2 		$3.57M Sell
250,096
-60,824
-20% -$1M ﹤0.01% 1559
2021
Q1 		$7.38M Buy
310,920
+190,101
+157% +$4.93M 0.01% 1050
2020
Q4 		$1.61M Buy
+120,819
New +$1.16M ﹤0.01% 1690

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

First Trust Advisors's IBRX Position: Q4 2025 in Review

First Trust Advisors sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 271,832 shares — an estimated $669K sold.

First Trust Advisors first reported a position in IBRX in Q4 2020 and held it in 12 quarters. The position peaked at $7.38M in Q1 2021. 276 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • First Trust Advisors reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • First Trust Advisors sold 271,832 ImmunityBio shares in Q4 2025, an estimated $669K.
  • First Trust Advisors first reported a position in ImmunityBio in Q4 2020 and held it in 12 quarters.
  • First Trust Advisors's ImmunityBio position peaked at $7.38M in Q1 2021.
  • 276 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on First Trust Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.